X0306 4 2019-04-17 0 0001217234 CareDx, Inc. CDNA 0001613855 Maag Peter C/O CAREDX, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005 1 1 0 0 See Remarks Common Stock 2019-04-17 4 M 0 4824 5.49 A 443230 D Common Stock 2019-04-17 4 M 0 30245 2.30 A 473475 D Common Stock 2019-04-17 4 M 0 14931 2.80 A 488406 D Common Stock 1000 I As UTMA custodian for minor child Common Stock 1000 I As UTMA custodian for minor child Employee Stock Option (right to buy) 5.49 2019-04-17 4 M 0 4824 0.00 D 2024-11-09 Common Stock 4824 18334 D Employee Stock Option (right to buy) 2.30 2019-04-17 4 M 0 30245 0.00 D 2027-02-17 Common Stock 30245 27500 D Employee Stock Option (right to buy) 2.80 2019-04-17 4 M 0 14931 0.00 D 2027-09-01 Common Stock 14931 10069 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The shares subject to the option vest in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination, (Continued from footnote 3) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. 1/4th of the shares subject to the option vested on January 27, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. 50% of the shares subject to the option vested on September 1, 2018 and 1/72nd of the shares subject to the option vest monthly thereafter. President and Chief Executive Officer /s/ Peter Maag 2019-04-18